TORONTO, June 28, 2018 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (“Acerus”) (TSX:ASP) today announced the voting results from its annual and special meeting of shareholders held on June 28, 2018 in Toronto, Ontario. The total number of shares represented in person or by proxy at the meeting was 129,800,500, representing 60.88% of the total issued and outstanding Acerus shares.

Election of Directors

The six (6) candidates nominated for election to the Acerus board of directors and listed in Acerus’ management information circular dated May 15, 2018, were elected by a majority of the shareholders present in person or represented by proxy at the meeting.  The voting results are as follows:

 Name Votes For (%) Votes Withheld (%)
 Ian O. Ihnatowycz 122,139,829 (96.61%) 4,284,000 (3.39%)
 Norma Beauchamp 124,800,379 (98.72%) 1,623,450 (1.28%)
 Borys Chabursky 126,021,079 (99.68%) 402,750 (0.32%)
 Stephen Gregory 121,647,329 (96.22%) 4,776,500 (3.78%)
 J. Mark Lievonen 122,480,919 (96.88%) 3,942,910 (3.12%)
 Edward Gudaitis 126,000,244 (99.66%) 423,585 (0.34%)

Appointment of Auditors

Acerus announced today that its shareholders have approved the re-appointment of PricewaterhouseCoopers LLP as the Auditor of Acerus to hold office until the next annual meeting of shareholders.

Ratification of Unallocated Entitlements under Acerus’ Stock Option Plan

Acerus announced today that its shareholders have approved a resolution to ratify the unallocated entitlements under its stock option plan.

Amendments to Acerus’ Stock Options Plan

Acerus also announced today that its shareholders have approved a resolution to make certain amendments to its stock option plan. 

About Acerus

Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve patient experience, with a primary focus in the field of men’s and women’s health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the U.S. and other territories.

Acerus currently has three marketed products: ESTRACE®, a product for the symptomatic relief of menopausal symptoms, is commercialized in Canada; NATESTO®, the first and only testosterone nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism, is commercialized in Canada and the U.S.; and UriVarx®, a Natural Health Product that helps reduce symptoms of hyperactive bladder such as daytime urinary frequency, urgency and nocturia. UriVarx® was recently approved by Health Canada and will be offered over-the-counter to Canadians dealing with such symptoms. Also, NATESTO® has been licensed for distribution in 48 additional countries worldwide. Marketing approvals in jurisdictions outside of North America are expected to take place over the course of the coming years. Acerus’ pipeline includes six innovative products: avanafil, a new chemical entity PDE5 inhibitor for the treatment of erectile dysfunction, which has been approved by the US FDA and the EU EMA and is commercialized in the US under the trade name STENDRA® and in the EU under the trade name SPEDRA®; SHACT™, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Elegant™ Vaginal Moisturizer, which provides comfort to women suffering from vaginal dryness, and Elegant™ pH, which is a pH balanced vaginal product; GYNOFLOR™, an ultra-low dose vaginal estrogen combined with a probiotic, for which a NDS has been filed in Canada for the treatment of vaginal atrophy, restoration of vaginal flora and treatment of certain vaginal infections; and TEFINA™, a clinical stage product aimed at addressing a significant unmet need for women with female sexual dysfunction. Finally, Acerus is working on expanding its product portfolio by leveraging its proprietary delivery systems, patents and formulation expertise. As such, Acerus has a number of products in various stage of development. One of these projects relates to cannabinoids (whether synthetic or naturally derived cannabinoids) to be delivered intranasally to patients, which may have multiple possible therapeutic applications (the “Cannabinoids Initiative”). Acerus has filed patent applications on the Cannabinoids Initiative, is currently working on setting up a series of pharmacokinetic clinical trials and is actively looking at potential partnering transactions for these initiatives.

Acerus’ shares trade on TSX under the symbol ASP. For more information, visit www.aceruspharma.com and follow us on Twitter and LinkedIn.

Notice regarding forward-looking statements

Information in this press release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 20, 2018 that is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Contact
Tricia Symmes
Chief Operating Officer
Acerus Pharmaceuticals Corporation
tsymmes@aceruspharma.com
(416) 509-2116